CONMED (US:CNMD)2026-01-28 22:30Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [5] - For the full year, sales were $1.375 billion, representing year-over-year growth of 5.2% as reported and 5.1% in constant currency [5] - Adjusted earnings per share for Q4 were $1.43, growing 6.7%, while full-year adjusted EPS was $4.59, growing 10.1% [5][21] - GAAP net income for Q4 was $16.7 million, down from $33.8 million in Q4 2024, with GAAP earnings per diluted share at $0.54 compared to $1.08 a year ago [19] Business Line Data and Key Metrics Changes - Orthopedic sales increased 12.1% in Q4 and 5.5% for the full year on a constant currency basis [5] - General surgery sales increased 3.8% in Q4 and 4.7% for the full year in constant currency [5] - U.S. orthopedic sales grew 6.6% in Q4, while international orthopedic sales increased 15.7% [16] - U.S. general surgery sales declined 0.4%, while international general surgery sales increased 14.8% [16] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased 1.4% [15] - The decline in U.S. general surgery was attributed to a focus on non-core areas and strategic portfolio management [16] Company Strategy and Development Direction - The company plans to exit its gastroenterology product lines to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery [6][7] - The strategy includes stabilizing and scaling operations to build a high-performance supply chain [8] - The company aims to deliver sustained above-market growth in its orthopedic portfolio over time [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to above-market growth by focusing on core strengths and investing in high-growth platforms [13] - The company is optimistic about the long-term growth potential of its AirSeal and BioBrace products, with expectations of high single-digit to low double-digit growth rates [10][12] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization [12] - The leverage ratio at the end of the year was 2.9 times, providing flexibility for innovation and growth [12] Q&A Session Summary Question: Can you talk about the cadence for the rest of the year and any selling day differences? - Management indicated no selling day differences and expected normal seasonality for the med tech calendar [30] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong teammate to the leadership team [32] Question: Can you clarify the organic revenue numbers presented at the healthcare conference versus today? - The difference was due to final numbers rolling out, with the current guidance being more precise [35] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales beat was attributed to committed sales professionals, improving supply chain, and new product approvals, while general surgery faced challenges due to portfolio management [37][40] Question: How will the GI business be reported going forward? - The GI business will be reported separately as the company moves forward [54]